4.30Open4.30Pre Close0 Volume2 Open Interest19.50Strike Price0.00Turnover0.00%IV13.04%PremiumMay 16, 2025Expiry Date2.02Intrinsic Value100Multiplier2DDays to Expiry2.28Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma9.82Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Teva Pharmaceutical Industries Stock Discussion
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
Gapping Up
$Gold Futures(JUN5) (GCmain.US)$ jump over 2% to above $3,300, while gold-related stocks surge in pre-market trading, with $Barrick Gold (GOLD.US)$ and $Newmont (NEM.US)$ climbing nearly 3%, $AngloGold Ashanti (AU.US)$ rising over 5%, and $Gold Fields (GFI.US)$ advancing over 6%.
$Teva Pharmaceutical Industries (TEVA.US)$ shares rose by over 6% in pre-market trading. Teva Pharmaceuticals and Alvotech annou...
FDA Grants Full Interchangeability to New Stelara Biosimilar for Multiple Autoimmune Conditions
$Ford Motor (F.US)$ stock rose 4% on Tuesday. The most traded calls are contracts of $9.5 strike price that expire on Apr 17 and the total volume reaching 52,829 with the open interest of 29,276.
Ford, GM, and about a dozen car parts suppliers might have their credit ratings downgraded soon if new tariffs from the Trump administration go into effect, says a report from S&P Global Ratings.
The rep...
Gapping Up
$Teva Pharmaceutical Industries (TEVA.US)$ rose by 4.9% as the company announced the FDA has accepted its filing for AJOVY for the prevention of episodic migraines in pediatric patients.
$Dollar Tree (DLTR.US)$ shares rose 1.3%, outperforming a declining market. Citi upgraded the stock to buy from neutral, calling it a "dark horse winner" in a global trade war.
Gapping Down
$Tesla (TSLA.US)$ led a major ...
Breakthrough: AJOVY Set to Become First CGRP Drug for Child Migraine Prevention
Can Teva's Injectable UZEDY Revolutionize Bipolar I Disorder Treatment? FDA Now Reviewing
Can This New IBD Drug Outperform Current Treatments? Phase 2b Data Shows Remarkable 48% Remission Rate
FDA-Approved SELARSDI Launches: What Makes This Stelara® Alternative Different?
No comment yet